Infographic: RA Perceptions
August 25, 2015 | Biologics, physicians, rheumatoid arthritis
HCPs predict the future of the biologics market
Findings from a recent survey of physicians across Europe has revealed that, despite stiff competition from newer biologics, biosimilars and pipeline agents, physicians expect current market leaders Enbrel (etanercept) and Humira (adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’ time. Nevertheless, the anti-TNF segment is predicted to experience a strong downturn with a 19% loss in share in the same period.
Download our RA Perceptions: Predicting the future of the European market infographic now »
RA Perceptions is a market research study which is carried out every month amongst a panel of 200 physicians across five European countries (France, Germany, Italy, Spain and the UK) and asks physicians about current and future perceptions of the RA market. These findings are from the June survey. RA Perceptions is a component of a larger ongoing patient tracking study called Therapy Watch RA, conducted by global healthcare market research specialist Research Partnership. An infographic highlights the key findings from the study.
Biologic agents with novel mechanisms of action (such as Roche’s RoActemra) are expected to outperform the overall EU biologics market with 15% growth over the next 3 years.
Biosimilars (the approved follow-on products to innovator biologics) will benefit from the greatest gains. Physicians predict a four-fold increase in their use of Hospira’s Inflectra and Celltrion’s Remsima. Despite heavy discounting of some biosimilars in certain markets such as France, the overall market share for these infliximab biosimilars is projected to remain relatively small. Less than 25% of physicians currently report prescribing biosimilars.
Overall, physicians’ awareness of pipeline agents in RA is low. The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative for patients who fail to respond adequately or are intolerant to traditional disease modifying treatments. Of the physicians who were familiar with these agents, 89% said they would prescribe Otezla and 83% stated they would prescribe Xeljanz, in the next 3 years.
The RA biologics market is expected to undergo significant changes in the next few years as newer entrants compete with established brands and biosimilars become increasingly accepted for use as cheaper alternatives to the branded biologics.
This content was provided by Inizio
Company Details
Latest Content from Inizio
How patient insights were brought to life with graphic novel outputs
Research Partnership’s client was developing a novel therapy for the treatment of a rare disease in which patients suffer acute symptomatic attacks; the main burden of disease is not just…
Research Partnership publishes new patient Living with Ankylosing Spondylitis & nr-axSpA EU & US 2019 reports
Living with Ankylosing Spondylitis (AS) & nr-AxSpA are reports based on quantitative studies conducted online in the 5EU and US. The AS 5EU report comprises of interviews with 385 patients…
Webinar: Usability and UX: You’ve been asked to test…What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST
Event: EphMRA Annual Conference
We’re sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland.
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
We are delighted to announce that an entry by Janssen and Research Partnership for the 2019 EphMRA MR Excellence Awards has been awarded runner-up in the ‘Business Impact through Innovation’…
Infographic: The vaccine opportunity in Asia
Asia is home to 60% of the world’s population and is one of the fastest growing vaccine markets in the world. A rising demand for better healthcare infrastructure and high…
Event: World Pharma Pricing and Market Access Congress
Directors Brett Gardiner and Rachel Howard attended the World Pharma Pricing and Market Access Congress in Amsterdam in March.This two-day event was attended by over 600 delegates, including a number…
Event: Intellus Worldwide Summit 2019
Visit us on stand number 311
Blog: The Future of Food Allergy? The Emergence of Targeted Allergy Treatments
Research Analyst Rachel Arthurs explores how public exposure to the complications of food allergy has affected attitudes toward treatment.In recent years, there has been a noticeable shift in the increased…
News: Research Partnership is listed in the Alantra Pharma Fast 50 annual report
The best performing privately-owned UK pharmaceutical businesses were revealed earlier this month with the publication of Pharma Times’ Alantra Pharma Fast 50 annual report.Read more about this report here